Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pharming Group N.V (PHAR) Receivables - Net: 2019-2024

Historic Receivables - Net for Pharming Group N.V (PHAR) over the last 6 years, with Dec 2024 value amounting to $54.8 million.

  • Pharming Group N.V's Receivables - Net fell 9.53% to $43.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.6 million, marking a year-over-year decrease of 9.53%. This contributed to the annual value of $54.8 million for FY2024, which is 18.77% up from last year.
  • According to the latest figures from FY2024, Pharming Group N.V's Receivables - Net is $54.8 million, which was up 18.77% from $46.2 million recorded in FY2023.
  • Over the past 5 years, Pharming Group N.V's Receivables - Net peaked at $54.8 million during FY2024, and registered a low of $27.6 million during FY2022.
  • In the last 3 years, Pharming Group N.V's Receivables - Net had a median value of $46.2 million in 2023 and averaged $42.9 million.
  • Per our database at Business Quant, Pharming Group N.V's Receivables - Net decreased by 16.48% in 2021 and then surged by 67.12% in 2023.
  • Over the past 5 years, Pharming Group N.V's Receivables - Net (Yearly) stood at $35.9 million in 2020, then fell by 16.48% to $30.0 million in 2021, then decreased by 7.88% to $27.6 million in 2022, then skyrocketed by 67.12% to $46.2 million in 2023, then climbed by 18.77% to $54.8 million in 2024.